More recently, advance immunotherapy for leukemia focused on CAR-T cells such as CD19-CAR-T for CD19+ lymphoid leukemia, and bispecific antibody such as a bispecific T cell engager antibody (BiTE, Blinatumomab), against CD19/CD3 for refractory acute lymphoid leukemia, however, the application is mostly limited in B cell lymphoid leukemia which express CD19, CD20 or CD22 etc [48–50]. This evidence concerns the gene CD19 and lymphoid leukemia.